Cue Biopharma, Inc. (CUE)
NASDAQ: CUE · Real-Time Price · USD
37.05
-0.79 (-2.09%)
At close: Sep 18, 2026, 4:00 PM EDT
37.63
+0.58 (1.57%)
After-hours: Sep 18, 2026, 7:37 PM EDT
Cue Biopharma Employees
Cue Biopharma had 29 employees as of December 31, 2025. The number of employees decreased by 12 or -29.27% compared to the previous year.
Employees
29
Change (1Y)
-12
Growth (1Y)
-29.27%
Revenue / Employee
$1,298,448
Profits / Employee
-$5,658,897
Market Cap
269.15M
Employees Chart
| Date | Employees | Change (1Y) | Growth (1Y) | Full-Time | Part-Time |
|---|---|---|---|---|---|
| Dec 31, 2025 | 29 | -12 | -29.27% | 29 | 0 |
| Dec 31, 2024 | 41 | -12 | -22.64% | 41 | 0 |
| Dec 31, 2023 | 53 | 1 | 1.92% | 53 | 0 |
| Dec 31, 2022 | 52 | -7 | -11.86% | 51 | 1 |
| Dec 31, 2021 | 59 | 7 | 13.46% | 57 | 2 |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Sep 30, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| MacroGenics | 293 |
| ProQR Therapeutics | 187 |
| Lyell Immunopharma | 161 |
| AC Immune | 122 |
| Lineage Cell Therapeutics | 77 |
| Upstream Bio | 75 |
| Immuneering | 57 |
| Pyxis Oncology | 56 |
CUE News
- 1 day ago - Cue Biopharma initiated with a Buy at B. Riley - TheFly
- 4 weeks ago - Cue Biopharma registers to sell 1.5M shares of common stock for holders - TheFly
- 5 weeks ago - Cue Biopharma Reports Second Quarter 2026 Financial Results and Recent Business Highlights - GlobeNewsWire
- 5 weeks ago - Cue Biopharma Quarterly report: Q2 2026 - Filings
- 5 weeks ago - Cue Biopharma Earnings release: Q2 2026 - Filings
- 5 weeks ago - Cue Biopharma Registration statement: Registration filing - Filings
- 6 weeks ago - Cue Biopharma appoints James Ahlers as CFO - TheFly
- 6 weeks ago - Cue Biopharma Announces Appointment of James M. Ahlers as Chief Financial Officer and CUE-221 Investigational New Drug Submission - GlobeNewsWire